http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Morita, Kyoji,Gotohda, Takako,Arimochi, Hideki,Lee, Mi-Sook,Her, Song Wiley Subscription Services, Inc., A Wiley Company 2009 Journal of neuroscience research Vol.87 No.11
<P>Progesterone treatment has previously been reported to promote the differentiation of glial cells probably through the production of 5α-reduced neurosteroids, resulting in the enhancement of serotonin-stimulated brain-derived neurotrophic factor (BDNF) gene expression, which is considered to contribute to the survival, regeneration, and plasticity of neuronal cells in the brain and hence has been suggested to improve mood disorders and other symptoms in depressive patients. Based on these previous observations, the effects on glial cells of histone deacetylase (HDAC) inhibitors, which are known as agents promoting cell differentiation, were examined using rat C6 glioma cells as a model for in vitro studies. Consequently, trichostatin A (TSA), sodium butyrate (NaB), and valproic acid (VPA) stimulated glial fibrillary acidic protein (GFAP) gene expression, and their stimulatory effects on GFAP gene expression were inhibited by treatment of these cells with finasteride, an inhibitor of the enzyme producing 5α-reduced neurosteroids. In addition, HDAC inhibitors enhanced serotonin-stimulated BDNF gene expression, the enhancement of which could be abolished by the inhibition of 5α-reduced neurosteroid production in the glioma cells. These results suggest that HDAC inhibitors may be able to promote the differentiation of rat C6 glioma cells through the production of 5α-reduced neurosteroids, resulting in the enhancement of serotonin-stimulated BDNF gene expression as a consequence of promoting their differentiation, indicating the possibility that differentiated glial cells may be implicated in preserving the integrity of neural networks as well as improving the function of neuronal cells in the brain. © 2009 Wiley-Liss, Inc.</P>
Increasing Needs of National Policy for Nicotine Dependence Treatments as a Part of Tobacco Control
Masakazu Nakamura,Takako Morita,Akira Oshima 대한암예방학회 2006 Journal of cancer prevention Vol.11 No.2
Tobacco use is the single most important preventable health risk in developed countries, and a major cause of premature death and disability worldwide. In 2000, tobacco smoking accounted for an estimated 113,000 of the total 962,000 deaths in Japan. In the Article 14 of the WHO Framework Convention for Tobacco Control (FCTC), countries are requested to take effective measures to promote cessation of tobacco use and adequate treatment for tobacco dependence. The essence of tobacco use is nicotine dependence. Nicotine dependence is a chronic disease that often requires repeated intervention. Environmental change strategies for tobacco control, such as tobacco taxation and smoking restriction in public places, can be effective in reducing tobacco use, but smokers often find it difficult to overcome their dependence without help. Effective treatments to promote smoking cessation need to be implemented in various health care settings as part of a comprehensive tobacco control measure. Lack of insurance coverage serves as barriers to use nicotine dependence treatment services. In countries where publicly funded health insurance exists, consideration should be given to making evidence-based tobacco dependence treatments reimbursable. (Cancer Prev Res 11, 85-88, 2006)